AHMED ELKHANANY to Receptor, ErbB-2
This is a "connection" page, showing publications AHMED ELKHANANY has written about Receptor, ErbB-2.
Connection Strength
0.258
-
Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2023 Feb; 197(3):673-681.
Score: 0.153
-
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol. 2023 12; 34(12):1131-1140.
Score: 0.041
-
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. Breast Cancer Res Treat. 2023 Apr; 198(2):217-229.
Score: 0.038
-
Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat. 2018 01; 167(1):89-99.
Score: 0.026